Christian Ellebæk Elling
Director/Board Member at IO BIOTECH, INC.
Net worth: - $ as of 30/05/2024
Network origin in Christian Ellebæk Elling first degree
Entity | Entity type | Industry | |
---|---|---|---|
Public Company | Biotechnology | 22 | |
7TM A/S
7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark.
9
| Private Company | Pharmaceuticals: Major | 9 |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark.
9
| Subsidiary | Biotechnology | 9 |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark.
8
| Holding Company | Biotechnology | 8 |
CytoKi Pharma ApS
CytoKi Pharma ApS Miscellaneous Commercial ServicesCommercial Services CytoKi Pharma ApS engages in the research and experimental development within biotechnology. It develops therapeutics for serious tissue and organ injuries. The company was founded by Rasmus Jørgensen on June 12, 2019 and is headquartered in Vaerlose, Denmark.
4
| Holding Company | Miscellaneous Commercial Services | 4 |
AFYX Therapeutics AS
AFYX Therapeutics AS Miscellaneous Commercial ServicesCommercial Services AFYX Therapeutics AS engages in research and development of pharmaceutical drugs. It develops a platform designed to deliver a pharmaceutical drug uni-directional to a mucosal surface. The company was founded in May 2014 and is headquartered in Virum, Denmark.
4
| Subsidiary | Miscellaneous Commercial Services | 4 |
SNIPR Biome ApS
SNIPR Biome ApS Pharmaceuticals: MajorHealth Technology SNIPR Biome ApS develops bacterial composition to provide treatment for diabetes to cancer. The company was founded by Christian Grøndal and is headquartered in Kongens Lyngby, Denmark.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Lundbeckfonden Emerge
Lundbeckfonden Emerge Investment ManagersFinance Lundbeckfonden Emerge (Emerge) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2012 and is headquartered in Copenhagen, Denmark.
3
| Operating Division | Investment Managers | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Christian Ellebæk Elling via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
University of Copenhagen | College/University | Doctorate Degree Undergraduate Degree Corporate Officer/Principal Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree Corporate Officer/Principal | |
NOVO NORDISK A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Technical University of Denmark | College/University | Graduate Degree Graduate Degree Graduate Degree Corporate Officer/Principal | |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
ALIGOS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman Director/Board Member | |
Copenhagen Business School | College/University | Graduate Degree Graduate Degree Graduate Degree | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Corporate Officer/Principal | |
NTG NORDIC TRANSPORT GROUP A/S | Trucking | Corporate Officer/Principal Corporate Officer/Principal Director/Board Member | |
Plexxikon, Inc.
Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA. | Miscellaneous Commercial Services | Director/Board Member Founder President | |
VELOXIS PHARMACEUTICALS A/S | Pharmaceuticals: Major | Director/Board Member Chairman Chairman | |
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
EpiTherapeutics ApS
EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
Draupnir Bio ApS
Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member | |
AMARIN CORPORATION PLC | Pharmaceuticals: Major | Chairman Director/Board Member | |
Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member Chairman | |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Investor | |
KERYX BIOPHARMACEUTICALS | Pharmaceuticals: Major | Director/Board Member Public Communications Contact | |
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
ONWARD MEDICAL N.V. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | Biotechnology | Director/Board Member Director/Board Member | |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Biotechnology | Director/Board Member Director/Board Member | |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Medical Specialties | Director/Board Member Director/Board Member | |
Vivet Therapeutics SAS
Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Director/Board Member | |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Thesan Pharmaceuticals, Inc.
Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member Director/Board Member | |
JenaValve Technology GmbH
JenaValve Technology GmbH Medical SpecialtiesHealth Technology JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany. | Medical Specialties | Corporate Officer/Principal Director/Board Member | |
Novo Holdings A/S (Investment Company)
Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Financial Conglomerates | Chief Investment Officer Corporate Officer/Principal | |
Kellogg School of Management | College/University | Masters Business Admin Masters Business Admin | |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Private Equity Investor | |
FIVE PRIME THERAPEUTICS, INC. | Biotechnology | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Biotechnology | Chairman Director/Board Member | |
CODEXIS, INC. | Chemicals: Specialty | Director/Board Member Director/Board Member | |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member | |
TREVI THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Chairman Director/Board Member | |
ZEALAND PHARMA A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member | |
Acesion Pharma ApS
Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
University of Zurich | College/University | Doctorate Degree Doctorate Degree | |
Symbion A/S
Symbion A/S General GovernmentGovernment Symbion A/S provides office communities, meeting facilities, conference facilities, business development and capital for start-up companies. The company was founded in 1986 and is headquartered in Copenhagen, Denmark. | General Government | Director/Board Member Corporate Officer/Principal |
Statistics
International
Denmark | 20 |
United States | 17 |
Switzerland | 5 |
Netherlands | 4 |
United Kingdom | 3 |
Sectoral
Health Technology | 33 |
Consumer Services | 6 |
Finance | 6 |
Commercial Services | 6 |
Transportation | 2 |
Operational
Director/Board Member | 332 |
Corporate Officer/Principal | 102 |
Independent Dir/Board Member | 72 |
Chairman | 53 |
Chief Executive Officer | 48 |
Most connected contacts
Insiders | |
---|---|
Claus Asbjørn Andersson | 41 |
Jack Nielsen | 38 |
Regina Hodits | 34 |
Mette Agger | 30 |
Stephan Christgau | 29 |
Roel Bulthuis | 29 |
Peter Moldt | 25 |
Jean Deleage | 23 |
Peter Chambré | 23 |
Michael Heffernan | 23 |
Emmanuelle Coutanceau | 21 |
Lars Ekman | 21 |
K. Hirth | 18 |
Kristine Peterson | 18 |
David Smith | 17 |
- Stock Market
- Insiders
- Christian Ellebæk Elling
- Company connections